Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cell-Therapy Deals A "Strategic Priority" For Shire

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.

You may also be interested in...

Juventas Moves Into Phase II With Funds From $22M Series B

Cleveland Clinic spinout Juventas Therapeutics raised $22 million that will help fund mid-stage studies of its adult stem cell treatment.

Pervasis Buyout Increases Shire’s Expertise In Regenerative Medicine

Specialty pharma says it will position ESRD candidate Vascugel for success, just as Shire is doing with Dermagraft, acquired in last year’s buyout of Advanced BioHealing.

Promethera's Cell Therapy Attracts Corporate VCs To Largest European Biopharma Funding Round This Year

Belgium's Promethera raises $31.4 million to start clinical trials of its cell therapy for orphan liver diseases in a Series B funding

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts